Alcoholic liver disease (ALD) is a complication that is a burden on global health and economy. Interleukin-33 (IL-33) is a newly identified member of the IL-1 cytokine family and is released as an "alarmin" during inflammation. Soluble suppression of tumourigenicity 2 (sST2), an IL-33 decoy receptor, has been reported as a new biomarker for the severity of systemic and highly inflammatory diseases. Here, we found the levels of plasma sST2, increased with the disease severity from mild to severe ALD. Importantly, the plasma sST2 levels in ALD patients not only correlated with scores for prognostic models (Maddrey's discriminant function, model for end-stage liver disease and Child-Pugh scores) and indexes for liver function (total bilirubin, international normalized ratio, albumin, and cholinesterase) but also correlated with neutrophil-associated factors as well as some proinflammatory cytokines. In vitro, lipopolysaccharide-activated monocytes down-regulated transmembrane ST2 receptor but up-regulated sST2 mRNA and protein expression and produced higher levels of tumour necrosis factor-α (TNF-α). By contrast, monocytes pretreated with recombinant sST2 showed decreased TNF-α production. In addition, although plasma IL-33 levels were comparable between healthy controls and ALD patients, we found the IL-33 expression in liver tissues from ALD patients was down-regulated at both RNA and protein levels. Immunohistochemical staining further showed that the decreased of IL-33-positive cells were mainly located in liver lobule area. These results suggested that sST2, but not IL-33, is closely related to the severity of ALD. Consequently, sST2 could be used as a potential biomarker for predicting the prognosis of ALD.
effective. 2 Liver transplantation is a good choice for ALD patients with severe liver dysfunction, as its outcome is better than in patients with other liver diseases. 3 However, several limitations, such as donors, waiting time, high cost, and multiple complications, restrict the use of liver transplantation.
Alcohol and its metabolite (acetaldehyde)-induced immune
response play an important role in driving the disease progression of ALD. For example, acetaldehyde binds to proteins and DNA to form autoantigens, which could induce mitochondria damage, impair glutathione function, and generate reactive oxygen species.
Alcohol abuse also results in colonic microbiota changes and increased intestinal permeability, which leads to elevated serum levels of lipopolysaccharide (LPS), increased LPS levels further trigger innate and adaptive immune responses resulting in proinflammatory cytokine production and pathogenic cell (neutrophils, monocytes) localization to the liver. [4] [5] [6] [7] More recently, strategies to
blockade proinflammatory cytokines have been tested in clinical trials. For instance, an IL-1R antagonist and an IL-1 inhibitor are being used in patients with severe AH, and IL-22 is being used in AH patients. 8 Identifying the characteristics of novel cytokines in a full-length transmembrane form (ST2L), a soluble form (sST2), and a novel variant. 12 The IL-33-ST2 axis is implicated in the pathogenesis of a variety of conditions, including asthma, rheumatoid arthritis, and Alzheimer's disease. [13] [14] [15] In the field of hepatology, the charac- mRNA expression levels were increased with the progression of the disease. To sum up, treatment with IL-33 attenuated hepatic steatosis induced by diet but aggravated hepatic fibrosis through an ST2-dependent manner. 16 In patients with hepatitis B virus infection or hepatitis C virus infection, plasma IL-33 levels were significantly increased, and the concentration changes were consistent with serum ALT levels. 17, 18 The protective role of the IL-33-ST2 axis in concanavalin A-induced severe hepatitis has received attention. After ST2-/-mice were treated with concanavalin A, they exhibited a high number of mononuclear cells in the liver and high levels of proinflammatory tumour necrosis factor (TNF)-α and interferon (IFN)-γ. Recently, Wang and coworkers found a dual role of the IL-33-ST2
axis during ALD development. In mice with mild ALD, ST2 dampened the inflammatory activation of hepatic macrophages through inhibiting the NF-κB pathway and played a protective role in an IL-33-independent manner. In contrast, at the later and severe stages of ALD, extracellular IL-33 was markedly increased, thus triggering IL-33-ST2 signalling and resulting in significant cell death and liver injury. 25 In the present study, we further assessed the characteristics of the IL-33-ST2 axis in a cohort of patients with ALD and found that serum sST2 levels were profoundly increased in patients with ALD and were closely associated with disease progression. Child-Pugh score -5 (5-8) 7 (5-11) 11 (8) (9) (10) (11) (12) (13) HC, healthy control; MALD, mild alcoholic liver disease; ALC, alcoholic liver cirrhosis; ALC+SAH, alcoholic liver cirrhosis superimposed severe alcoholic hepatitis; WBC, white blood cell; NEU#, absolute value of neutrophils; LYM#, absolute value of lymphocytes; NLR, neutrophil-to-lymphocyte ratio; HGB, haemoglobin; PLT, platelet; PT, prothrombin time; INR, international normalized ratio; ALT, alanine aminotransferase; AST, aspartate transaminase; TBIL, total bilirubin; ALB, albumin; CHE, cholinesterase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; CR, creatinine; MDF, Maddrey's discriminant function; MELD, model for end-stage liver disease. Data are shown as number (%) or median (range).
| MATERIALS AND METHODS

| Patients
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| 889 5′ -GAAGGCACACCGTAAGACTA -3′; reverse primer, 5′ -GACAAACCAACGATAGGAGG -3′). β-Actin was used as an endogenous control (forward primer, 5′ -CATGTACGTTGCTATCCAGGC -3′; reverse primer, 5′-CTCCTTAATGTCACGCACGAT -3′). These primers were synthesized by Invitrogen (Beijing, China). The specificity of the amplification was determined by melting curve analysis. The relative fold change in each gene was calculated using the 2(−ΔΔC(T)) method. 29 
| Western blot analysis
Proteins were extracted from the liver tissues, and the concentrations were determined using the Bradford method. A total of 30 μg 
| Immunohistochemical staining
Formalin-fixed, paraffin-embedded liver tissue sections were incubated with an anti-IL-33 antibody overnight at 4°C after boiling in an ethylenediaminetetraacetic acid antigen retrieval solution (pH 8.0) at 98°C for 10 min for antigen-epitope retrieval and blocking endogenous peroxidase activity with 0.3% hydrogen peroxide. Then, the sections were incubated for 30 minutes with poly HRP-anti-Mo/Rb IgG secondary antibody (Zsbio, Beijing, China) at 37°C, and staining was performed using 3-amino-9-ethylcarbazole (AEC, red colour) as a colorimetric substrate, followed by counterstaining with haematoxylin.
The IL-33 expression levels for the semiquantitative assay were measured with Image-Pro Plus 6.0 software (Media Cybernetics, CA, USA) and expressed as the integrated optical density (IOD) parameter.
| Monocyte isolation and activation
CD14 + monocytes were separated using a Pan Monocyte Isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. The purity of the separated monocytes was >90%. The purified monocytes were activated using LPS (1000 ng/mL, Sigma, St. Louis, USA) or an equal volume of normal saline for 6 h. After stimulation, the supernatant from the culture was used for sST2 detection, and adherent monocytes were collected for surface ST2 detection and message ST2 detection.
For investigating the effect of sST2 on monocytes, purified monocytes were pretreated with or without recombinant sST2
(rsST2, 100 ng/mL, R&D Systems, Minneapolis, MN, USA) for 1 h and were further stimulated with 1000 ng/mL LPS or an equal volume of normal saline for 6 h. Subsequently, the levels of TNF-α production in monocytes were detected by flow cytometry. were associated with ALD severity
| Flow cytometric analysis
We measured plasma IL-33 and sST2 levels in a cohort of patients with ALD and HCs. We found that the plasma levels of IL-33 were similar between the HCs and all of the patients with ALD, and no differences were observed between each group ( Figure 1A ).
We then detected the plasma levels of sST2, which were significantly higher in patients with ALD (median 54.0 ng/mL, range 13.1-90.5 ng/mL) than in the HCs (median 21.6 ng/mL, range 6.6-51. were further increased compared to those in ALC patients without severe liver damage (HC vs ALC: P < 0.001, HC vs ALC+SAH: P < 0.001, MALD vs ALC: P = 0.004, MALD vs ALC+SAH: P < 0.001, ALC vs ALC+SAH: Figure 1B) .
We analysed the correlations between plasma sST2 concentrations and the prognostic model scores in the ALD patients. Plasma sST2 levels correlated positively with both MDF scores (r = 0.753, P < 0.001) and with MELD scores (r = 0.607, P < 0.001). Increased sST2 levels were also correlated positively with the Child-Pugh score (r = 0.464, P = 0.003, Figure 1C ) within ALC patients (ALC and ALC+SAH groups). These data suggested that the increased plasma levels of sST2 were associated with the ALD severity.
| Assessment of the potential correlations
between sST2 levels and liver damage markers, liver proteosynthetic and reserve function, and neutrophil-associated indexes Alanine aminotransferase (ALT) and aspartate transaminase (AST) are important indicators of early liver damage. However, we did not observe any correlation between plasma sST2 levels and ALT or AST levels ( Figure 2A ). By contrast, sST2 levels were positively correlated with serum total bilirubin levels (TBIL, r = 0.661, P < 0.001) and the international normalized ratio (INR, r = 0.713, P < 0.001, Figure 2B ), both of which are markers for later liver damage.
Albumin (ALB) and cholinesterase (CHE) were used to reflect the liver proteosynthetic and reserve function. We observed inverse correlations between plasma sST2 and serum ALB (r = −0.384, P = 0.008) and CHE (r = −0.635, P < 0.001, Figure 2C) levels.
Neutrophils are considered to be the primary cell type responsible for liver damage in ALD, and the neutrophil-to-lymphocyte ratio (NLR) was recently identified to be associated with adverse prognosis in some diseases. 30 We found positive correlations between sST2 levels and the absolute value of neutrophils (NEU#, r = 0.390, P = 0.007) and the NLR (r = 0.497, P < 0.001, Figure 2D ). These results suggest a link between sST2 levels and the immune response involving neutrophils. Figure 3A and B). We observed that sST2 levels were positively correlated with IL-1β and IL-6 levels (IL-1β, r = 0.347, P = 0.018; IL-6, r = 0.561, P < 0.001).
Intestinal fatty acid binding protein (I-FABP) is expressed in epithelial cells and released when intestinal mucosal damage
occurs. 31 We found that serum I-FABP levels were significantly increased in ALD patients (HC: median 1.9 ng/mL, range 0.6-3.2 ng/ mL, ALD: median 4.4 ng/mL, range 0.6-10.9 ng/mL, HC vs ALD: Figure 3C ). However, no correlation was observed between plasma sST2 levels and I-FABP.
Serum sCD14 levels can be used as a marker for LPS bioactivity in HIV infection. 32 However, the plasma levels of sCD14
were not different between HCs and ALD patients, and no correlation was observed between plasma sST2 and sCD14 levels (Figure 3D ).
| LPS-activated monocytes were one of the major cell types involved in sST2 production
ST2L is expressed mainly on various haematopoietic cells, including
Th2 cells, mast cells, and eosinophils. 33, 34 However, the cell types associated with sST2 are unclear. We further investigated whether monocytes were associated with ST2. Transmembrane receptor were markedly higher than those in the paired control group (34.37 ± 11.30 pg/mL, P = 0.018, Figure 4C ).
| sST2 attenuated TNF-α production from LPS-activated monocytes
TNF-α has been reported to be one of representative proinflammatory cytokines produced through NF-κB pathway in monocytes. 35 To detect the effect of sST2 on monocyte responses, monocytes isolated from patients with ALD were stimulated with LPS in the presence or absence of rsST2. As showed in Figure 5 , monocytes produced higher levels of TNF-α after stimulated by LPS, suggested LPS effectively activates NF-κB pathway in vitro (TNF-α + CD14 + %, control group: 1.89 ± 0.50; LPS group: 41.50 ± 17.44, P = 0.001). Of note, rsST2 itself has no effect on inducing TNF-α production from monocytes. Importantly, we found that pre-rsST2-treated monocytes significantly down-regulate TNF-α production in response to LPS, suggested sST2 partially attenuated the response of LPS-activated monocytes (LPS+rsST2 group: 33.14 ± 18.54, P = 0.018).
| IL-33 expression was decreased in the livers of ALD patients
We further examined whether there was a difference in IL-33 expression in the livers of ALD patients and HCs. The heatmap in Figure 6A shows that IL-33 gene expression slightly decreased in MALD group, whereas no difference was observed in the ST2 levels.
IL-33 and ST2 gene expression was further validated by qPCR. In agreement with the microarray data, IL-33 mRNA levels were lower in the livers of MALD patients than in those of the HCs (HCs:
1.00 ± 0.20; MALD: 0.72 ± 0.06, P = 0.032, Figure 6B ), whereas ST2L and sST2 mRNA levels were similar between the two groups.
We then evaluated IL-33 protein levels by Western blot. As shown by the densitometry results in Figure 6C , 27 kD IL-33 levels, but not 43 kD IL-33 levels, were significantly down-regulated in ALC patients (HCs: 1.00 ± 0.38; ALC: 0.31 ± 0.18, P = 0.029).
We also detected the distribution of IL-33-positive cells in the livers of ALC patients and HCs. We found that IL-33 protein was stained negatively in hepatocytes, while the detectable IL-33 + cells
were located in the inflammatory portal areas and in hepatic sinusoids in the lobule areas. As shown in Figure 6D , the relative levels 
| DISCUSSION
The IL-33-ST2 axis has been reported to be involved in a variety of liver diseases; recently, an unanticipated role of this axis has been demonstrated in a mouse model of ALD. 25 In the present study, we further investigated the characteristics of the IL-33-ST2 axis in a cohort of patients with ALD. We found that serum sST2, but not IL-33, levels were increased in patients with ALD. Thus, serum sST2 levels could be a promising biomarker in predicting the clinical outcomes of ALD.
Previous studies have reported that sST2 can be used as a prognostic biomarker for the development of systemic and highly inflammatory diseases, such as aortic dissection, sepsis, and heart failure as well as mortality in patients with these diseases. [36] [37] [38] This hypothesis is reinforced by the finding that plasma sST2 concentrations could predict poor prognosis in patients with acute-on-chronic hepatitis B liver failure. 39 The present study further revealed its prognostic increased serum concentrations of sST2 in patients with acute-onchronic hepatitis B liver failure, 39 we also observed that sST2 positively correlated with TBIL levels and the INR, both of which are primary factors for evaluating liver failure. 40 These data indicated that sST2 correlated with the disease progression of ALD. Third, sST2 levels showed a strong positive correlation with MDF scores; scores greater than 32 indicated that the ALD patient was in a severe, lifethreatening condition according to this scoring system. 41 In addition, sST2 positively correlated with MELD scores; the higher this score was, the more urgent the need for liver transplantation was. 42 What is more, sST2 also positively correlated with Child-Pugh scores; this is the most commonly used scoring system for evaluating the prognosis of liver cirrhosis. 43 Taken together, these observations indicate that plasma sST2 concentrations in ALD patients have prognostic value in predicting clinical outcomes.
Importantly, our data also revealed a clear correlation between plasma sST2 concentrations and proinflammatory markers. In this regard, neutrophils are one of the key pathogenic cell types in ALD. 44 We found that sST2 positively correlated with the neutrophil number and NLR. This association was further supported by the data that sST2 positively correlated with the proinflammatory cytokines IL-1β and IL-6. This observation is clinically relevant as both IL-1β
and IL-6 plasma levels are involved in inducing liver injury in patients with ALD. 45 Thus, the plasma sST2 level is a good indicator of inflammatory levels in ALD patients.
Previous studies suggested that IL-33 exerts anti-inflammatory properties in models of heart disease, obesity, and uveitis. The protective properties of IL-33 are associated with increased circulating Th2 cytokine levels, decreased IFN-γ production, increased eosinophil numbers, and type 2 innate lymphoid cells. 46 More recently, IL-33 has also been shown to mediate immunosuppression and tissue repair by activating regulatory T cells (Treg) and promoting M2 macrophage polarization. 47 In the present study, we investigated the characteristics of IL-33 in a cohort of ALD patients and found that the levels of IL-33 in liver tissues were decreased in patients with MALD and ALC. This finding was in line with the available observation that the liver IL-33 concentration was decreased in HBV-ACLF patients with accompanying liver cirrhosis. 39 Thus, we may speculate that by interfering with IL-33, the increased sST2 levels further block bioactivity with respect to the function of IL-33. Liver cirrhosis is the consequence of progressive fibrosis; the present study, in contrast to a recent report of IL-33-ST2 axis characteristics in a mouse model of AH and fibrosis, 25 further extends the characteristics of the IL-33-ST2 axis in this type of patients.
The detailed bioactivity of sST2 remains unknown in ALD patients. Clinically, ALC is usually accompanied by portal hypertension and increased gut permeability, both of which contribute to the accumulation of pathogen-associated molecules, such as LPS, in the blood circulation. 48 In the present study, we found that serum I-FABP levels, a marker for gut permeability, were significantly increased in ALD patients. Furthermore, LPS-activated monocytes produced sST2 as well as some proinflammatory cytokines, such as TNF-α, which has been proved to be involved in the pathogenesis of ALD. 49 It has been found that both serum and liver levels of TNF-α increased in ALD patients. 50 Our experiments have shown that sST2 administration could attenuate an LPS challenge and down-regulate the inflammatory or activation processes, evident by the down-regulation of LPS-induced TNF-α production in monocytes. Therefore, we hypothesized that the sST2 production of LPS-activated monocytes may be a protective feedback mechanism responding to inflammatory stress. Notably, a previous study found that vein and arterial endothelial cells, as well as microvascular endothelial cells, express sST2 under stress and hypertension conditions. 51 Future studies should investigate whether portal hypertension is related to the increased plasma sST2 levels in ALD patients.
Taken together, our data show that high plasma levels of sST2 are associated with prognostic scores for disease progression and correlate well with biomarkers for inflammation. These results, for
the first time, demonstrate the characteristics of the IL-33-ST2 axis in a cohort of patients with ALD, including liver cirrhosis with severe hepatitis. Our findings suggest that levels of serum sST2, but not IL-33, are closely related to the severity of ALD and could be used as a potential biomarker for predicting the prognosis of ALD.
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